Search Results

ValnevaSE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and IDT Biologika today announced they have agreed to terminate their collaboration following the delivery of inactivated COVID-19 bulk vaccine to Valneva, and considering the current order levels and existing inventories.

IDT Biologika, a leading Contract Development and Manufacturing Organization specialized in vaccines, gene and immune therapy and oncolytic viruses based in Germany, and Exothera S.A. collaborate to develop a large-scale manufacturing process for viral vector-based vaccines.

IDT Biologika, a globally integrated contract manufacturer of vaccines and biopharmaceuticals, honored with six 2019 CMO Leadership Awards in all categories, including Capabilities, Compatibility, Expertise, Quality, Reliability and Service.

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine

IDT Biologika announced that the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the United States Department of Health and Human Services, has awarded the company a new Task Order within the 10-year Indefinite Delivery, Indefinite Quantity contract no.

IDT Biologika announced that the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the United States Department of Health and Human Services, has awarded the company a new Task Order within the 10-year Indefinite Delivery, Indefinite Quantity contract no. HHSN272201800011I to provide process development activities and production of a vaccine against the Respiratory Syncytial Virus.